Corre, J., Vincent, L., Moreau, P., Hebraud, B., Hulin, C., Béné, M. C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., Facon, T., Lambert, J., Leleu, X., Macro, M., Perrot, A., Zweegman, S., Filleron, T., Cabarrou, B., Donk, N. W. C. J. V. D., Mahéo, S., Hua, W., Wang, J., Krevvata, M., Vanquickelberghe, V., Boer, C. D., Tuozzo, A., Borgsten, F., Rowe, M., Carson, R., Wuilleme, S., Sonneveld, P. (2025). Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results. Blood. https://doi.org/10.1182/blood.2024027620